Redeye raises Q-linea’s fair value based on a stronger belief in the strength of the Thermo Fisher deal than previously expected and execution according to plan. We have also lowered our required rate of return. (WACC to 10% vs 12% previously). The company has a very exciting year ahead with the upcoming prospective study during H2 this year and the process for CE-IVD approval to be able to launch ASTar on the market during 2021. Our new motivated value in the base case is SEK 175 (SEK 87).

info@redeye.se (Redeye.se)

Redeye AB - Redeye.se